ES2578327T3 - Uso de oligosacáridos sintéticos polisulfatados como agentes de desbridamiento de una herida - Google Patents

Uso de oligosacáridos sintéticos polisulfatados como agentes de desbridamiento de una herida Download PDF

Info

Publication number
ES2578327T3
ES2578327T3 ES11712922.1T ES11712922T ES2578327T3 ES 2578327 T3 ES2578327 T3 ES 2578327T3 ES 11712922 T ES11712922 T ES 11712922T ES 2578327 T3 ES2578327 T3 ES 2578327T3
Authority
ES
Spain
Prior art keywords
polysulphated
wound debridement
synthetic oligosaccharides
degradation
fibrin matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11712922.1T
Other languages
English (en)
Inventor
Laurent Apert
Christelle Laurensou
Dominique Nicot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urgo Recherche Innovation et Developpement
Original Assignee
Urgo Recherche Innovation et Developpement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urgo Recherche Innovation et Developpement filed Critical Urgo Recherche Innovation et Developpement
Application granted granted Critical
Publication of ES2578327T3 publication Critical patent/ES2578327T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Composición que comprende al menos un compuesto seleccionado entre los oligosacáridos sintéticos polisulfatados con de 1 a 4 unidades de monosacáridos, sus sales y complejos, para su uso como agente de desbridamiento de una herida.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
Durante las primeras 24 horas de incubación a 37 °C, ha surgido así una matriz de fibrina que tiene aproximadamente la apariencia de un gel.
Al cabo de 24 horas, la observación microscópica de esta matriz de fibrina, mostró la formación de una red de 5 filamentos homogénea.
2. Demostración del efecto de la sal de potasio del octasulfato de sacarosa sobre la degradación de la matriz de fibrina.
10 24 h después del inicio de la formación de la matriz de fibrina en el tubo de 15 ml antes mencionado, se añadió una solución de sal de potasio del octasulfato de sacarosa en una cantidad de 1 volumen de solución de este compuesto por 5 volúmenes de la mezcla de fibrinógeno/trombina utilizada para la preparación de la matriz de fibrina.
En paralelo, se preparó una solución de control libre del compuesto de prueba con una solución salina amortiguada 15 con fosfato (PBS: solución salina amortiguada con fosfato).
Se monitorizó visualmente la degradación de la matriz de fibrina durante las 24 y 48 horas siguientes.
Las observaciones hechas así se clasificaron en tres niveles:
20 -No hay degradación: la matriz sigue siendo la misma. -Degradación parcial: desagregación de la matriz. -Degradación total: la matriz desaparece.
25 3. Determinación de los PDF:
Con el fin de cuantificar y de verificar que las observaciones realizadas corresponden bien a una degradación de la matriz de fibrina, se determinaron los productos de degradación de la fibrina (PDF) 24 horas o 48 horas después de la adición de las soluciones del compuesto de prueba.
30 Esta determinación se realizó de acuerdo con una técnica convencional utilizando un kit de determinación de PDF plasma de referencia 00540 comercializado por la compañía Diagnostica Stago.
Se toman así 20 μl de sobrenadante en el tubo de 15 ml que se colocó en el centro del anillo rojo de una placa del kit 35 de determinación de PDF. Se añadieron 20 μl de suspensión de partículas de látex. Después de agitar, se realizó el análisis.
Al correlacionar los resultados visuales y las medidas de PDF, se cuantificaron los resultados obtenidos:
40 -si el valor de los PDF, expresado en µg/ml, es menor que 5, no hay ninguna degradación de la matriz de fibrina, -si el valor de los PDF, expresado en µg/ml, está comprendido entre 5 y 20, hay una degradación parcial de la matriz de fibrina, -si el valor de los PDF, expresado en µg/ml, es mayor que 20, hay una degradación total de la matriz de fibrina que desaparece. 45
4. Pruebas con la sal de potasio del octasulfato de sacarosa:
Se preparó una solución acuosa de sal de potasio del octasulfato de sacarosa a 10 g/litro.
50 Esta solución se probó de acuerdo con el protocolo descrito anteriormente y se midieron los PDF 48 horas después de añadir la solución a la matriz de fibrina.
Para obtener una evaluación de la relevancia de los resultados, se probó como control negativo una solución de PBS y como control positivo el producto Accuzyme® que contiene como enzima proteolítica papaína, asociada a la 55 urea y que se utiliza en el contexto del desbridamiento enzimático.
Al medir los PDF, se obtuvieron los siguientes resultados:
-PBS: inferior a 5 µg/ml 60 -Accuzyme®: superior a 20 µg/ml -Solución a 10 g/l de sal de potasio del octasulfato de sacarosa: comprendida entre 5 y 20 µl/ml.
Se demostró así la eficacia de la sal de potasio del octasulfato de sacarosa que se tradujo en una degradación parcial de la matriz de fibrina. 65
8
imagen7
imagen8

Claims (1)

  1. imagen1
ES11712922.1T 2010-02-17 2011-02-16 Uso de oligosacáridos sintéticos polisulfatados como agentes de desbridamiento de una herida Active ES2578327T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1051142A FR2956322A1 (fr) 2010-02-17 2010-02-17 Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
FR1051142 2010-02-17
PCT/FR2011/050329 WO2011101594A1 (fr) 2010-02-17 2011-02-16 Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie

Publications (1)

Publication Number Publication Date
ES2578327T3 true ES2578327T3 (es) 2016-07-26

Family

ID=42813433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11712922.1T Active ES2578327T3 (es) 2010-02-17 2011-02-16 Uso de oligosacáridos sintéticos polisulfatados como agentes de desbridamiento de una herida

Country Status (16)

Country Link
US (1) US8940325B2 (es)
EP (1) EP2536413B1 (es)
JP (2) JP5889804B2 (es)
KR (1) KR101846036B1 (es)
CN (1) CN102762212B (es)
AU (1) AU2011217040B2 (es)
BR (1) BR112012020739A2 (es)
CA (1) CA2788350C (es)
ES (1) ES2578327T3 (es)
FR (2) FR2956322A1 (es)
MX (1) MX336870B (es)
PL (1) PL2536413T3 (es)
PT (1) PT2536413T (es)
RU (1) RU2601899C2 (es)
SG (1) SG182798A1 (es)
WO (1) WO2011101594A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2956322A1 (fr) * 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2993182B1 (fr) * 2012-07-13 2014-10-17 Urgo Lab Pansement a liberation prolongee d'actifs
CN102755664B (zh) * 2012-07-20 2014-03-26 河南科技大学 用于寒区外伤创面的急救敷料及其制备方法
FR2999581B1 (fr) * 2012-12-18 2015-05-01 Urgo Lab Procede d'incorporation d'agents actifs au sein d'une mousse polyurethane hydrophile
US10113879B2 (en) * 2014-03-03 2018-10-30 Apple Inc. Hierarchy of tools for navigation
FR3026949A1 (fr) * 2014-10-09 2016-04-15 Urgo Lab Composition cosmetique et/ou dermatologique pour la prevention et le traitement des varices sous cutanees
CN107429029B (zh) 2015-04-06 2021-04-16 3M创新有限公司 可移除的成膜凝胶组合物及其施用方法
CN104926889A (zh) * 2015-05-24 2015-09-23 广西师范学院 蔗糖硫酸酯铜银类化合物及其制作方法和用途
WO2017173240A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
JP2020500860A (ja) 2016-11-23 2020-01-16 ゴジョ・インダストリーズ・インコーポレイテッド プロバイオティック／プレバイオティックな有効成分を含む消毒薬組成物
FR3064488B1 (fr) 2017-03-31 2021-01-01 Urgo Rech Innovation Et Developpement Composition contenant un derive de cellulose, un plastifiant, un solvant volatil et un actif, ses utilisations comme pansement

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869530B (en) * 1985-12-24 1987-10-28 Marion Laboratories Inc Use of synthetic sulfated saccharides to enhance wound healing
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5908836A (en) * 1987-12-21 1999-06-01 Bar-Shalom; Daniel Protecting skin from radiation damage using sulphated sugars
DK86492D0 (da) * 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
AUPO976897A0 (en) * 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
GB2362100B (en) * 2000-05-08 2002-05-08 Maelor Pharmaceuticals Ltd Wound gels
GB2392913B (en) * 2002-09-11 2007-04-04 Johnson & Johnson Medical Ltd Wound dressings comprising complexes of oxidised celluloses with silver
PT1536845E (pt) * 2002-09-11 2007-06-01 Johnson & Johnson Medical Ltd Materiais de penso compreendendo complexos de polissacarídeos aniónicos com prata
US7829543B2 (en) * 2003-01-07 2010-11-09 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
US8039017B2 (en) * 2003-06-19 2011-10-18 Coloplast A/S Wound care device
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
DE602005008964D1 (de) * 2005-09-16 2008-09-25 Italfar Societa A Responsabili Wundheilende pharmazeutische Zusammensetzung enthaltend Sucralfat, Glycin, Aluminium Acetat und Vitamine
US8277849B2 (en) * 2006-01-19 2012-10-02 Solazyme, Inc. Microalgae-derived compositions for improving the health and appearance of skin
RU2384338C2 (ru) * 2008-02-13 2010-03-20 Сергей Георгиевич Павленко Композиция для лечения гнойных ран и трофических язв
FR2956322A1 (fr) * 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.

Also Published As

Publication number Publication date
BR112012020739A2 (pt) 2016-04-26
FR2956322A1 (fr) 2011-08-19
US8940325B2 (en) 2015-01-27
AU2011217040A1 (en) 2012-09-06
AU2011217040B2 (en) 2015-03-26
PL2536413T3 (pl) 2016-11-30
KR20120138742A (ko) 2012-12-26
KR101846036B1 (ko) 2018-05-18
CN102762212A (zh) 2012-10-31
FR2976082B1 (fr) 2018-05-04
CA2788350A1 (fr) 2011-08-25
SG182798A1 (en) 2012-09-27
JP5889804B2 (ja) 2016-03-22
FR2976082A1 (fr) 2012-12-07
US20130034596A1 (en) 2013-02-07
MX336870B (es) 2016-02-04
JP2016020376A (ja) 2016-02-04
PT2536413T (pt) 2016-08-29
EP2536413A1 (fr) 2012-12-26
WO2011101594A1 (fr) 2011-08-25
MX2012009675A (es) 2013-02-11
RU2601899C2 (ru) 2016-11-10
JP2013519713A (ja) 2013-05-30
EP2536413B1 (fr) 2016-06-01
RU2012137955A (ru) 2014-03-27
CN102762212B (zh) 2014-11-26
CA2788350C (fr) 2018-10-16

Similar Documents

Publication Publication Date Title
ES2578327T3 (es) Uso de oligosacáridos sintéticos polisulfatados como agentes de desbridamiento de una herida
BR112017010268A2 (pt) agente de ligação; composição de diagnóstico; kit de diagnóstico; métodos de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral; para descartar uma infecção bacteriana em um indivíduo; para descartar uma infecção viral em um indivíduo; para considerar uma infecção bacteriana em um indivíduo; para considerar uma infecção viral em um indivíduo; para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo; para fornecer uma recomendação de tratamento para um indivíduo; para fornecer uma recomendação de teste de diagnóstico para um indivíduo; para descartar uma doença infecciosa; para identificação do tipo de infecção; e dispositivo para o diagnóstico de infecções bacterianas
BR112014031573A2 (pt) painel acústico e uso de um painel acústico
AR105497A1 (es) Prueba mejorada de endotoxina bacteriana para la determinación de endotoxinas
BR112014026582A2 (pt) método para identificar agentes capazes de induzir a sensibilização respiratória e matriz e kits analíticos para uso no método
PE20150964A1 (es) Formulaciones acuosas estables de adalimumab
BR112014020083A8 (pt) Dispositivos indicadores biológicos de esterilização e métodos de uso
ES2530467T3 (es) Sistema y procedimiento para la comunicación entre diferentes entidades mediante el uso de diferentes porciones de datos para diferentes canales
CL2013003000A1 (es) Composicion farmaceutica para el cuidado oral, que comprende una sal de calcio y una fuente de fosfato soluble; metodo para blanquear y remineralizar los dientes; y uso de dicha composicion en la remineralizacion, sensibilidad disminuida y/o blanqueamiento de los dientes y combinaciones de los mismos.
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
BR112013020653A2 (pt) sistema de monitoração de consumo de energia, método e programa de computador
BR112012017264A2 (pt) medição de teor de gás de rochas reservatórios não convencionais
AR091386A1 (es) Composiciones detergentes autoadhesivas con sistemas que cambian de color
CO6680654A2 (es) Composiciones y métodos para mejorar la compatibilidad de las sales herbicídas solubles en agua
BR112013004771A2 (pt) dispositivo para uso em um sistema de conferência digital
AR095964A1 (es) Formulaciones para la preservación de órganos y tejidos con mayor estabilidad y vida útil
PE20150083A1 (es) Formulacion de ibuprofeno inyectable
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
ES2580377T3 (es) Método para cultivar células en un medio que contiene lisado de plaquetas
BR112015013071A2 (pt) solução de trombina e seus métodos de uso
WO2010041865A3 (ko) 메틸렌블루의 색상 변화를 이용한 정액 진단 방법, 진단 키트 및 이를 이용하여 품질 판단 가능한 정액
AR098194A1 (es) Ensayos de líneas de células t de humanos para evaluar la identidad inmunológica de preparaciones de acetato de glatiramero
AR087709A1 (es) Autonegociacion de frecuencia adaptada
CN203852372U (zh) B超探头与指针板联动装置
TWI796653B (zh) 細胞培養組合物及其用途